ArticleKidney & blood pressure research2026
Prognostic Value of Claims Data for Chronic Kidney Disease-Associated Health Risks.
Article in Kidney & blood pressure research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic kidney disease (CKD) associates with kidney failure and overall health risks. We here investigated the prognostic value of claims data in the absence of biochemical data.
methodsA total of 29,144 persons insured at AOK Rhineland-Hamburg with a diagnosis of CKDIII or CKDIV in 2016 were included in analyses of renal replacement therapy (rRT), death, hospital admissions and diagnoses, and prescription of CKD-related therapies during the ensuing 6-year period (2017-2022) using corresponding billing codes.
resultsIn 22,228 individuals diagnosed with CKDIII and 6,916 with CKDIV during the base year, rRT was prescribed in 3.8% and 14.3% during the observation period; 7.0% and 13.3% were admitted to the hospital for acute kidney injury (AKI). A combination of claims data significantly contributed to the prognosis of rRT (AUC 0.87) and AKI (AUC 0.68) and overall outcomes, death (AUC 0.97), hospital admission for heart failure (AUC 0.76), and intensive care unit (ICU) therapy (AUC 0.67). All AUCs significantly improved after inclusion of CKD stage into the model. Outpatient prescriptions of renin-angiotensin system and sodium-glucose cotransporter 2 (SGLT2) inhibitors are associated with significantly better renal and cardiovascular outcomes. Prescription of CKD-related pharmacotherapy for calcium metabolism (AUC 0.74), hyperkalemia/hyperphosphatemia (AUC 0.83), metabolic acidosis (AUC 0.81), erythropoiesis-stimulating agents (AUC 0.65), and hyperuricemia therapy (AUC 0.72) was prognosticated by claims data with significant contribution of CKD stage. SUMMARY AND
conclusionClaims data provide prognostic information for renal and overall outcomes in CKDIII and CKDIV patients even in the absence of laboratory measurements. Inclusion of additional values should be evaluated in patients with and without CKD for individualized risk calibration.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.